News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
170,866 Results
Type
Article (7354)
Company Profile (61)
Press Release (163451)
Section
Business (56263)
Career Advice (292)
Deals (10516)
Drug Delivery (18)
Drug Development (14216)
Employer Resources (22)
FDA (3868)
Job Trends (4121)
News (85427)
Policy (6098)
Tag
Academia (880)
Alliances (18270)
Alzheimer's disease (285)
Approvals (3868)
Artificial intelligence (87)
Bankruptcy (36)
Best Places to Work (3652)
Biotechnology (41)
Breast cancer (65)
Cancer (440)
Career advice (259)
Cell therapy (76)
Clinical research (10630)
Collaboration (202)
COVID-19 (540)
C-suite (46)
Data (376)
Diabetes (35)
Diagnostics (3628)
Drug discovery (33)
Earnings (17224)
Events (21872)
Executive appointments (135)
FDA (4055)
Featured Employer (27)
Funding (103)
Gene editing (23)
Gene therapy (46)
GLP-1 (94)
Government (834)
Healthcare (5704)
Infectious disease (556)
Inflammatory bowel disease (27)
Interviews (38)
IPO (3493)
Job creations (559)
Job search strategy (228)
Layoffs (43)
Legal (1062)
Lung cancer (61)
Lymphoma (31)
Manufacturing (76)
Medical device (3639)
Medtech (3641)
Mergers & acquisitions (7131)
Metabolic disorders (71)
Neuroscience (342)
NextGen Class of 2024 (1821)
Non-profit (1076)
Northern California (448)
Obesity (35)
Opinion (30)
People (17301)
Phase I (3861)
Phase II (4567)
Phase III (3424)
Pipeline (133)
Postmarket research (361)
Preclinical (2240)
Press Release (42)
Radiopharmaceuticals (90)
Rare diseases (35)
Real estate (1657)
Regulatory (4502)
Research institute (1016)
Resumes & cover letters (41)
Southern California (284)
Startups (925)
United States (3723)
Vaccines (64)
Date
Today (34)
Last 7 days (163)
Last 30 days (620)
Last 365 days (9537)
2024 (9493)
2023 (11165)
2022 (14149)
2021 (15494)
2020 (15460)
2019 (13996)
2018 (10471)
2017 (8926)
2016 (8400)
2015 (9503)
2014 (6669)
2013 (5529)
2012 (6050)
2011 (6509)
2010 (5375)
Location
Africa (158)
Arizona (31)
Asia (11700)
Australia (1408)
California (893)
Canada (337)
China (125)
Colorado (53)
Connecticut (30)
Europe (24130)
Florida (132)
Georgia (29)
Illinois (121)
Indiana (87)
Maryland (157)
Massachusetts (634)
Michigan (59)
Minnesota (86)
New Jersey (328)
New York (229)
North Carolina (230)
Northern California (448)
Ohio (64)
Pennsylvania (158)
South America (266)
Southern California (284)
Tennessee (26)
Texas (151)
Utah (53)
Washington State (77)
170,866 Results for "integral molecular".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Integrated DNA Technologies and Molecular Health Ink Commercial Partnership
Genomics solutions provider Integrated DNA Technologies (IDT) and Bio-IT company Molecular Health have entered into a global multi-year agreement, starting in the U.S., to integrate their next generation sequencing (NGS) capabilities.
May 15, 2024
·
6 min read
Drug Development
Molecular Glue Degraders at Inflection Point as Pharma Dives In
Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.
December 16, 2024
·
6 min read
·
Kate Goodwin
Pharm Country
Integral Molecular Launches Virus Neutralization Assay Services to Drive Antiviral Discovery
Integral Molecular announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and therapeutic antibodies.
April 16, 2024
·
2 min read
Pharm Country
Integral Molecular Achieves ISO 9001 Certification for its Membrane Proteome Array Service
Integral Molecular proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ specificity testing services.
March 27, 2024
·
2 min read
Business
Integral Molecular Enters Into Exclusive Antibody License With Seismic Therapeutic
Integral Molecular, a leading biotech company specializing in antibody discovery against undruggable protein targets, announced today that it has entered into an antibody license agreement with Seismic Therapeutic.
January 4, 2024
·
2 min read
Earnings
Biogen Tops Wall Street Expectations for Leqembi, Inks Molecular Glue Deal
Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with Neomorph to discover and develop molecular glue degraders.
October 30, 2024
·
2 min read
·
Heather McKenzie
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
Press Releases
BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2024 Annual Meeting
November 21, 2024
·
3 min read
Pharm Country
Integral Molecular Launches TiterSafe™ Influenza Virus-Like Particles for Safe and Convenient Vaccine Testing
Integral Molecular, a leading provider of reagents for vaccine evaluation, announces the launch of TiterSafe™ influenza virus-like particles, an off-the-shelf virus-alternative for key experiments in testing influenza vaccines.
November 7, 2023
·
2 min read
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period
QIAGEN announced a decision to discontinue the NeuMoDx 96 and 288 Molecular Systems in light of the market development trends for these product lines following the COVID-19 pandemic and changing customer needs for integrated PCR-based clinical molecular testing systems.
June 6, 2024
·
7 min read
1 of 17,087
Next
